drugset / Trial / NCT06903377
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.
Timeline
- Start
- 2025-05-23
- Primary completion
- 2027-04
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gecacitinib | Unknown | 50 mg | Oral |
| Subject | Gecacitinib | Unknown | 100 mg | Oral |
| Subject | ZG005 | Unknown | 20 mg/kg | Intravenous |